<div class="table-wrap">
<div id="ehy310-T1" data-id="ehy310-T1" class="table-wrap-title">
<div class="label -label">Table 1</div>
<div class="caption"><p>Baseline
 clinical characteristics of the CANTOS population in the placebo group 
and in the canakinumab groups according to achieved concentrations of 
interleukin-6 above or below the median 3 month on-treatment value of 
1.65 ng/L</p></div> </div>
<div class="table-overflow"><table>
<thead name="thead" align=""><tr>
<th>Baseline characteristics </th>
<th>Placebo (<em>n</em> = 1597) </th>
<th>Canakinumab, 3 month on-treatment Il-6 above the median value (≥1.65 ng/L) (<em>n</em> = 1619) </th>
<th>Canakinumab, 3-month on-treatment IL-6 below the median value (&lt;1.65 ng/L) (<em>n</em> = 1617) </th>
</tr></thead>
<tbody>
<tr>
<td>Age (years) </td>
<td>62.0 (55.0–69.0) </td>
<td>64.0 (57.0–70.0) </td>
<td>60.0 (53.0–67.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Female sex </td>
<td>413 (25.9) </td>
<td>399 (24.6) </td>
<td>417 (25.8) </td>
</tr>
<tr>
<td>Region </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Asia </td>
<td>96 (6.0) </td>
<td>95 (5.9) </td>
<td>94 (5.8)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td> Central Europe </td>
<td>260 (16.3) </td>
<td>276 (17.1) </td>
<td>271 (16.8) </td>
</tr>
<tr>
<td> Latin America </td>
<td>110 (6.9) </td>
<td>126 (7.8) </td>
<td>72 (4.5) </td>
</tr>
<tr>
<td> North America </td>
<td>587 (36.8) </td>
<td>555 (34.3) </td>
<td>632 (39.1) </td>
</tr>
<tr>
<td> Western Europe </td>
<td>544 (34.1) </td>
<td>567 (35.0) </td>
<td>548 (33.9) </td>
</tr>
<tr>
<td>Current smoking </td>
<td>397 (24.9) </td>
<td>486 (30.0) </td>
<td>389 (24.1)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>) </td>
<td>30.4 (27.0–34.9) </td>
<td>30.8 (27.2–35.1) </td>
<td>30.1 (24.1–33.9)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Waist circumference (cm) </td>
<td>106.0 (97.0–117.0) </td>
<td>107.3 (98.1–118.0) </td>
<td>105.0 (96.0–114.3)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Hypertension </td>
<td>1285 (80.5) </td>
<td>1365 (84.3) </td>
<td>1284 (79.4)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Diabetes </td>
<td>681 (42.6) </td>
<td>740 (45.7) </td>
<td>586 (36.2)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Qualifying myocardial infarction </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> STEMI </td>
<td>791 (49.5) </td>
<td>811 (50.1) </td>
<td>855 (52.9) </td>
</tr>
<tr>
<td> Non-STEMI </td>
<td>574 (35.9) </td>
<td>571 (35.3) </td>
<td>556 (34.4) </td>
</tr>
<tr>
<td> Unknown/missing </td>
<td>232 (14.5) </td>
<td>236 (14.6) </td>
<td>206 (12.7) </td>
</tr>
<tr>
<td>History of PCI </td>
<td>1067 (66.8) </td>
<td>1096 (67.8) </td>
<td>1139 (70.4) </td>
</tr>
<tr>
<td>History of CABG </td>
<td>269 (16.8) </td>
<td>323 (20.0) </td>
<td>205 (12.7)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>History of congestive heart failure </td>
<td>306 (19.2) </td>
<td>390 (24.1) </td>
<td>249 (15.4)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Lipid lowering therapy </td>
<td>1494 (93.6) </td>
<td>1500 (92.8) </td>
<td>1518 (94.1) </td>
</tr>
<tr>
<td>Renin-angiotensin inhibitors </td>
<td>1250 (78.6) </td>
<td>1304 (80.9) </td>
<td>1283 (79.6) </td>
</tr>
<tr>
<td>Anti-ischaemia agents<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
<td>1477 (92.5) </td>
<td>1503 (93.0) </td>
<td>1476 (91.5) </td>
</tr>
<tr>
<td>hsCRP (mg/L) </td>
<td>4.15 (2.80–6.85) </td>
<td>4.90 (3.15–8.20) </td>
<td>3.70 (2.55–5.90)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Interleukin-6 (ng/L) </td>
<td>2.58 (1.78–4.03) </td>
<td>3.54 (2.43–5.50) </td>
<td>1.93 (1.45–2.63)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Total cholesterol (mg/dL) </td>
<td>162.0 (139.6–189.0) </td>
<td>159.3 (134.6–187.9) </td>
<td>163.1 (140.9–191.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL) </td>
<td>83.9 (66.1–107.0) </td>
<td>82.0 (63.0–106.0) </td>
<td>84.0 (65.4–108.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL) </td>
<td>45.6 (38.7–53.8) </td>
<td>43.0 (36.4–52.0) </td>
<td>45.4 (38.0–54.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Triglycerides (mg/dL) </td>
<td>138.1 (100.1–195.7) </td>
<td>136.4 (100.1–192.0) </td>
<td>139.1 (103.6–195.7) </td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m<sup>2</sup>) </td>
<td>79.0 (65.0–93.0) </td>
<td>75.0 (60.0–90.0) </td>
<td>79.0 (67.0–93.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Randomized to canakinumab 50 mg </td>
<td> </td>
<td>617 (38.1) </td>
<td>401 (24.8)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Randomized to canakinumab 150 mg </td>
<td> </td>
<td>570 (35.2) </td>
<td>568 (35.1) </td>
</tr>
<tr>
<td>Randomized to canakinumab 300 mg </td>
<td> </td>
<td>432 (26.7) </td>
<td>648 (40.1) </td>
</tr>
</tbody>
</table></div>
<div content-id="ehy310-T1" class="table-modal"><table>
<thead name="thead" align=""><tr>
<th>Baseline characteristics </th>
<th>Placebo (<em>n</em> = 1597) </th>
<th>Canakinumab, 3 month on-treatment Il-6 above the median value (≥1.65 ng/L) (<em>n</em> = 1619) </th>
<th>Canakinumab, 3-month on-treatment IL-6 below the median value (&lt;1.65 ng/L) (<em>n</em> = 1617) </th>
</tr></thead>
<tbody>
<tr>
<td>Age (years) </td>
<td>62.0 (55.0–69.0) </td>
<td>64.0 (57.0–70.0) </td>
<td>60.0 (53.0–67.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Female sex </td>
<td>413 (25.9) </td>
<td>399 (24.6) </td>
<td>417 (25.8) </td>
</tr>
<tr>
<td>Region </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> Asia </td>
<td>96 (6.0) </td>
<td>95 (5.9) </td>
<td>94 (5.8)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td> Central Europe </td>
<td>260 (16.3) </td>
<td>276 (17.1) </td>
<td>271 (16.8) </td>
</tr>
<tr>
<td> Latin America </td>
<td>110 (6.9) </td>
<td>126 (7.8) </td>
<td>72 (4.5) </td>
</tr>
<tr>
<td> North America </td>
<td>587 (36.8) </td>
<td>555 (34.3) </td>
<td>632 (39.1) </td>
</tr>
<tr>
<td> Western Europe </td>
<td>544 (34.1) </td>
<td>567 (35.0) </td>
<td>548 (33.9) </td>
</tr>
<tr>
<td>Current smoking </td>
<td>397 (24.9) </td>
<td>486 (30.0) </td>
<td>389 (24.1)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>) </td>
<td>30.4 (27.0–34.9) </td>
<td>30.8 (27.2–35.1) </td>
<td>30.1 (24.1–33.9)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Waist circumference (cm) </td>
<td>106.0 (97.0–117.0) </td>
<td>107.3 (98.1–118.0) </td>
<td>105.0 (96.0–114.3)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Hypertension </td>
<td>1285 (80.5) </td>
<td>1365 (84.3) </td>
<td>1284 (79.4)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Diabetes </td>
<td>681 (42.6) </td>
<td>740 (45.7) </td>
<td>586 (36.2)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Qualifying myocardial infarction </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td> STEMI </td>
<td>791 (49.5) </td>
<td>811 (50.1) </td>
<td>855 (52.9) </td>
</tr>
<tr>
<td> Non-STEMI </td>
<td>574 (35.9) </td>
<td>571 (35.3) </td>
<td>556 (34.4) </td>
</tr>
<tr>
<td> Unknown/missing </td>
<td>232 (14.5) </td>
<td>236 (14.6) </td>
<td>206 (12.7) </td>
</tr>
<tr>
<td>History of PCI </td>
<td>1067 (66.8) </td>
<td>1096 (67.8) </td>
<td>1139 (70.4) </td>
</tr>
<tr>
<td>History of CABG </td>
<td>269 (16.8) </td>
<td>323 (20.0) </td>
<td>205 (12.7)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>History of congestive heart failure </td>
<td>306 (19.2) </td>
<td>390 (24.1) </td>
<td>249 (15.4)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Lipid lowering therapy </td>
<td>1494 (93.6) </td>
<td>1500 (92.8) </td>
<td>1518 (94.1) </td>
</tr>
<tr>
<td>Renin-angiotensin inhibitors </td>
<td>1250 (78.6) </td>
<td>1304 (80.9) </td>
<td>1283 (79.6) </td>
</tr>
<tr>
<td>Anti-ischaemia agents<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
<td>1477 (92.5) </td>
<td>1503 (93.0) </td>
<td>1476 (91.5) </td>
</tr>
<tr>
<td>hsCRP (mg/L) </td>
<td>4.15 (2.80–6.85) </td>
<td>4.90 (3.15–8.20) </td>
<td>3.70 (2.55–5.90)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Interleukin-6 (ng/L) </td>
<td>2.58 (1.78–4.03) </td>
<td>3.54 (2.43–5.50) </td>
<td>1.93 (1.45–2.63)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Total cholesterol (mg/dL) </td>
<td>162.0 (139.6–189.0) </td>
<td>159.3 (134.6–187.9) </td>
<td>163.1 (140.9–191.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL) </td>
<td>83.9 (66.1–107.0) </td>
<td>82.0 (63.0–106.0) </td>
<td>84.0 (65.4–108.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL) </td>
<td>45.6 (38.7–53.8) </td>
<td>43.0 (36.4–52.0) </td>
<td>45.4 (38.0–54.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Triglycerides (mg/dL) </td>
<td>138.1 (100.1–195.7) </td>
<td>136.4 (100.1–192.0) </td>
<td>139.1 (103.6–195.7) </td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m<sup>2</sup>) </td>
<td>79.0 (65.0–93.0) </td>
<td>75.0 (60.0–90.0) </td>
<td>79.0 (67.0–93.0)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Randomized to canakinumab 50 mg </td>
<td> </td>
<td>617 (38.1) </td>
<td>401 (24.8)<a reveal-id="tblfn1" data-open="tblfn1" class="link link-ref link-reveal xref-fn">*</a> </td>
</tr>
<tr>
<td>Randomized to canakinumab 150 mg </td>
<td> </td>
<td>570 (35.2) </td>
<td>568 (35.1) </td>
</tr>
<tr>
<td>Randomized to canakinumab 300 mg </td>
<td> </td>
<td>432 (26.7) </td>
<td>648 (40.1) </td>
</tr>
</tbody>
</table></div>
<div class="table-wrap-foot"><div content-id="tblfn1"><div class="fn">
<div class="label -label">*</div>
<p><em>P</em> &lt; 0.05.</p>
</div></div></div>
</div>